Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-07
DOI
10.1038/s41375-021-01218-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
- (2021) Mikkael A. Sekeres et al. LEUKEMIA
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
- (2020) David A Sallman et al. BLOOD
- APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)
- (2020) Thomas Cluzeau et al. BLOOD
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine
- (2020) Guillermo Garcia-Manero et al. BLOOD
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer
- (2020) Andrea J. Luker et al. BMC IMMUNOLOGY
- 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-mediated Apoptosis.
- (2020) Sha Jin et al. CLINICAL CANCER RESEARCH
- Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients
- (2020) Shanshan Pei et al. Cancer Discovery
- Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis
- (2020) Yang Cao et al. BIOMEDICINE & PHARMACOTHERAPY
- Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML
- (2020) Guillermo Garcia-Manero et al. BLOOD
- Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity are Linked to Clinical Responses to 5-Azacytidine
- (2020) Hitoshi Ohtani et al. CANCER RESEARCH
- Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
- (2020) Curtis Andrew Lachowiez et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).
- (2020) Courtney Denton Dinardo et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
- (2020) Haley E. Ramsey et al. Targeted Oncology
- Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia
- (2020) Emily Gruber et al. LEUKEMIA
- Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network
- (2020) Xiaorong Gu et al. LEUKEMIA
- Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study
- (2020) Shyamala C. Navada et al. LEUKEMIA RESEARCH
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
- (2020) Gerwin Huls et al. Blood Advances
- Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells
- (2020) Yong-Rim Kwon et al. Experimental Hematology & Oncology
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
- (2020) Andrew H. Wei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Can we predict responsiveness to hypomethylating agents in AML?
- (2019) Julia Stomper et al. SEMINARS IN HEMATOLOGY
- An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
- (2019) Michael R Savona et al. Lancet Haematology
- Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
- (2019) Guillermo Garcia-Manero et al. Lancet Haematology
- 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes
- (2019) Anja L. Gawlitza et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles
- (2019) Gail J. Roboz et al. BLOOD
- Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
- (2019) Chenchen Zhao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response
- (2019) David Sharon et al. Science Translational Medicine
- Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
- (2019) Thomas Oellerich et al. Nature Communications
- Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection
- (2019) Francisco Caiado et al. Nature Communications
- Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial
- (2019) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes
- (2018) Marcos de Lima et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis
- (2018) Paolo Fagone et al. JOURNAL OF NEUROIMMUNOLOGY
- Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
- (2018) Naval Daver et al. LEUKEMIA
- RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia
- (2018) Jason X. Cheng et al. Nature Communications
- DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
- (2018) Na Luo et al. Nature Communications
- Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
- (2018) Andrea Kuendgen et al. Oncotarget
- A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML
- (2018) Amir T. Fathi et al. BLOOD
- A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies (GFM)
- (2018) Lionel Ades et al. HAEMATOLOGICA
- Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
- (2018) Daniel A. Pollyea et al. NATURE MEDICINE
- Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis
- (2018) Sebastian Klobuch et al. Frontiers in Pharmacology
- Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
- (2017) Bruno C. Medeiros et al. HAEMATOLOGICA
- Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells
- (2017) Jihao Zhou et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117
- (2017) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo
- (2017) Matthew L. Cooper et al. JOURNAL OF IMMUNOLOGY
- Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
- (2017) Hagop M Kantarjian et al. LANCET ONCOLOGY
- AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo
- (2017) A Unnikrishnan et al. LEUKEMIA
- Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine
- (2017) Marie Sébert et al. LEUKEMIA RESEARCH
- BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
- (2017) Valérie Vidal et al. Oncotarget
- Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
- (2017) Ashwin Unnikrishnan et al. Cell Reports
- Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
- (2017) Bruno C. Medeiros et al. HAEMATOLOGICA
- Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy
- (2016) Wei Wu et al. ANNALS OF HEMATOLOGY
- Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts
- (2016) S. Vasu et al. BLOOD
- A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
- (2016) Sai Krishna Athuluri-Divakar et al. CELL
- Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
- (2016) Guillermo Garcia-Manero et al. LANCET ONCOLOGY
- Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
- (2016) G L Uy et al. LEUKEMIA
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
- (2016) Jane Merlevede et al. Nature Communications
- A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
- (2016) Jeannine Diesch et al. Clinical Epigenetics
- Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells
- (2015) Kumiko Ueda et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft
- (2015) J Steinmann et al. BONE MARROW TRANSPLANTATION
- DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
- (2015) David Roulois et al. CELL
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
- (2015) Kristen Meldi et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
- (2015) Jean-Pierre J Issa et al. LANCET ONCOLOGY
- Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia
- (2015) Claudio Fozza et al. LEUKEMIA RESEARCH
- Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
- (2015) Stéphanie Harel et al. LEUKEMIA RESEARCH
- Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
- (2015) Andreas D. Ørskov et al. Oncotarget
- Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome
- (2015) Ebba Sohlberg et al. Oncotarget
- DNA methyltransferase inhibition accelerates the immunomodulation and migration of human mesenchymal stem cells
- (2015) Seunghee Lee et al. Scientific Reports
- Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
- (2015) Eric Laille et al. PLoS One
- BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
- (2015) Thomas Cluzeau et al. Oncotarget
- Both mature KIR+ and immature KIR- NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice
- (2014) A. Kubler et al. BLOOD
- Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
- (2014) H. Dohner et al. BLOOD
- Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
- (2014) Jean-Pierre Issa et al. CANCER
- Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia
- (2014) S. Thomas et al. HAEMATOLOGICA
- Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
- (2014) Thomas Prebet et al. JOURNAL OF CLINICAL ONCOLOGY
- Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine
- (2014) Vu H. Duong et al. LEUKEMIA & LYMPHOMA
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
- (2013) Eleni D. Lagadinou et al. Cell Stem Cell
- Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
- (2013) R. Z. Mahfouz et al. CLINICAL CANCER RESEARCH
- Mechanisms of resistance to azacitidine in human leukemia cell lines
- (2013) Piyanuch Sripayap et al. EXPERIMENTAL HEMATOLOGY
- Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
- (2013) A Valencia et al. LEUKEMIA
- Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
- (2013) T Schroeder et al. LEUKEMIA
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
- (2012) O. C. Goodyear et al. BLOOD
- Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice
- (2012) Pierre L. Triozzi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome
- (2012) B. Costantini et al. HAEMATOLOGICA
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
- (2012) C Craddock et al. LEUKEMIA
- Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
- (2012) Ellen K. Ritchie et al. LEUKEMIA & LYMPHOMA
- Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
- (2011) J. M. Scandura et al. BLOOD
- Impact of the hypomethylating agent 5-azacytidine on dendritic cells function
- (2011) Jihane Frikeche et al. EXPERIMENTAL HEMATOLOGY
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
- (2011) Thomas Prébet et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
- (2011) Taichun Qin et al. PLoS One
- Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation
- (2010) Benjamin J. Schmiedel et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting of 5-aza-2′-deoxycytidine residues by chromatin-associated DNMT1 induces proteasomal degradation of the free enzyme
- (2010) Katan Patel et al. NUCLEIC ACIDS RESEARCH
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting
- (2009) L. I. Sanchez-Abarca et al. BLOOD
- Chemical Decomposition of 5-Aza-2′-deoxycytidine (Decitabine): Kinetic Analyses and Identification of Products by NMR, HPLC, and Mass Spectrometry
- (2009) Daniel K. Rogstad et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Targeting DNA Methylation
- (2009) J.-P. J. Issa et al. CLINICAL CANCER RESEARCH
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation
- (2009) M. Rius et al. MOLECULAR CANCER THERAPEUTICS
- Demethylating treatment suppresses natural killer cell cytolytic activity
- (2009) Xiao-ning Gao et al. MOLECULAR IMMUNOLOGY
- Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
- (2008) T. Qin et al. BLOOD
- Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
- (2008) Gautam Borthakur et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation